Bank of New York Mellon’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Bank of New York Mellon’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-35,287	Closed	-$185K	–	4300
2024 Q1	$185K	Sell	35,287 -6,548	-16%	-$35.9K	﹤0.01%	3953
2023 Q4	$219K	Sell	41,835 -21,394	-34%	-$211K	﹤0.01%	3924
2023 Q3	$997K	Sell	63,229 -1,008	-2%	-$18.1K	﹤0.01%	3147
2023 Q2	$1.25M	Sell	64,237 -49,176	-43%	-$1.17M	﹤0.01%	3076
2023 Q1	$3.22M	Sell	113,413 -6,327	-5%	-$188K	﹤0.01%	2534
2022 Q4	$3.5M	Buy	119,740 +13,423	+13%	+$427K	﹤0.01%	2542
2022 Q3	$2.81M	Buy	106,317 +3,793	+4%	+$139K	﹤0.01%	2618
2022 Q2	$4.55M	Sell	102,524 -13,345	-12%	-$613K	﹤0.01%	2367
2022 Q1	$5.74M	Sell	115,869 -8,780	-7%	-$421K	﹤0.01%	2343
2021 Q4	$6.35M	Sell	124,649 -923	-0.7%	-$47.8K	﹤0.01%	2340
2021 Q3	$7M	Buy	125,572 +10,477	+9%	+$515K	﹤0.01%	2322
2021 Q2	$4.93M	Sell	115,095 -4,964	-4%	-$205K	﹤0.01%	2491
2021 Q1	$5.01M	Sell	120,059 -8,243	-6%	-$383K	﹤0.01%	2447
2020 Q4	$5.98M	Sell	128,302 -1,419	-1%	-$66.4K	﹤0.01%	2278
2020 Q3	$5.51M	Buy	129,721 +16,466	+15%	+$720K	﹤0.01%	2162
2020 Q2	$5.43M	Buy	113,255 +3,444	+3%	+$172K	﹤0.01%	2171
2020 Q1	$5.05M	Sell	109,811 -7,128	-6%	-$358K	﹤0.01%	2069
2019 Q4	$7.03M	Sell	116,939 -6,415	-5%	-$383K	﹤0.01%	2165
2019 Q3	$6.98M	Sell	123,354 -5,360	-4%	-$301K	﹤0.01%	2124
2019 Q2	$7.17M	Sell	128,714 -4,261	-3%	-$222K	﹤0.01%	2156
2019 Q1	$6.71M	Sell	132,975 -4,209	-3%	-$187K	﹤0.01%	2193
2018 Q4	$5.53M	Sell	137,184 -40,435	-23%	-$2.08M	﹤0.01%	2230
2018 Q3	$12.3M	Buy	177,619 +23,903	+16%	+$1.81M	﹤0.01%	1905
2018 Q2	$11.6M	Buy	153,716 +6,310	+4%	+$397K	﹤0.01%	1943
2018 Q1	$7.77M	Sell	147,406 -7,479	-5%	-$435K	﹤0.01%	2118
2017 Q4	$8.28M	Buy	154,885 +20,608	+15%	+$1.15M	﹤0.01%	2083
2017 Q3	$8.01M	Buy	134,277 +17,767	+15%	+$1.07M	﹤0.01%	2096
2017 Q2	$9.19M	Buy	116,510 +482	+0.4%	+$39.4K	﹤0.01%	2014
2017 Q1	$9.62M	Sell	116,028 -580	-0.5%	-$43.1K	﹤0.01%	1996
2016 Q4	$9.25M	Buy	116,608 +23,343	+25%	+$1.7M	﹤0.01%	1994
2016 Q3	$6.53M	Buy	93,265 +51,725	+125%	+$2.87M	﹤0.01%	2104
2016 Q2	$1.61M	Buy	41,540 +658	+2%	+$27.4K	﹤0.01%	2846
2016 Q1	$1.66M	Sell	40,882 -21,230	-34%	-$1.35M	﹤0.01%	2766
2015 Q4	$5.51M	Buy	62,112 +437	+0.7%	+$34.5K	﹤0.01%	2157
2015 Q3	$4.57M	Sell	61,675 -4,859	-7%	-$404K	﹤0.01%	2286
2015 Q2	$5.38M	Buy	66,534 +35,258	+113%	+$2.3M	﹤0.01%	2310
2015 Q1	$1.31M	Buy	+31,276	New	+$887K	﹤0.01%	3135

Other funds holding EGRX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon's EGRX Position: Q2 2024 in Review

Bank of New York Mellon sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 35,287 shares — an estimated $185K sold.

Bank of New York Mellon first reported a position in EGRX in Q1 2015 and held it in 37 quarters. The position peaked at $12.3M in Q3 2018. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

Bank of New York Mellon reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
Bank of New York Mellon sold 35,287 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $185K.
Bank of New York Mellon first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 37 quarters.
Bank of New York Mellon's Eagle Pharmaceuticals, Inc. position peaked at $12.3M in Q3 2018.
75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.